Prof. R. (Ronald) de Wit, PhD

I am Medical Oncologist, senior staff member and full professor at the Erasmus MC Cancer Institute.

My research focus is Genito-Urinary Oncology. I have chaired the EORTC-Genitourinary Group Chemotherapy Subcommittee for many years and initiated and led randomized studies in testicular cancer, renal, prostate and bladder cancer. I am still involved in a wide variety of ongoing clinical and translational studies. I supervise 6-8 PhD students in the field of clinical and preclinical reserarch in GU cancers.

My research focus is Genito-Urinary Oncology.

I co-chaired several registration trials, ranging from chemotherapy and AR targeted agents in mCRPC, to recent checkpoint inhibition (PD-1) trials in bladder cancer. I am currently involved in a wide variety of ongoing clinical studies and serve on Industry Advisory Board Committees, as well as Data Monitoring Committees.

In 2011 I launched the Dutch Uro Oncology Study Group (www.stichtingduos.nl) creating a collaborative network of 25 hospitals in the Netherlands and am Chairman of the Group.

I earned my medical degree at the University of Amsterdam and specialized in Internal Medicine and Medical Oncology (1982-1990).After obtaining my PhD (HIV-associated cancer 1990).

I continued my career at the ErasmusMC Cancer Institute, formerly Daniel den Hoed Cancer Center. In 2009 I obtained a full professorship in Experimental systemic treatment of Genito-Urinary cancers.

Post-graduate lecturer on the management of GU cancers for ESMO, aside from the annual main European meeting, I give annual lectures at ESMO-Americas, ESMO-Africa, ESMO-Middle East and ESMO-Asia.

Founding ( 2011) Chairman of the Dutch Uro-Oncology Study group, a network comprising 26 university and supraregional hospitals in the Netherlands. Member of a wide range of professional societies and committees; serving as Faculty and Program Committee Member/ Committee Chair for the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO).

Research groups:

The clinical research program in Genito-urinary Oncology comprises the entire spectrum of phase 1-3 clinical trials, both Industry as well as investigator initiated studies and is embedded in the Department’s research programs Translational Cancer Genomics and Proteomics, Translational Pharmacology and Translational Onco-Immunology. Clinical and preclinical research activities are highly complementary: findings coming forth from preclinical studies are assessed for their clinical value and clinical questions lead to novel preclinical studies. There is well-established collaboration with the Departments of Urology, Uro-Pathology, Molecular Diagnostic Pathology, and Radiotherapy. There is an extensive collaboration with partners from academia and industry, both nationally and internationally.

Research projects:

The clinical research program in Genito-urinary Oncology, including the entire spectrum of phase 1-3 clinical trials, both Industry as well as investigator initiated studies, is embedded in the Department’s research programs Translational Cancer Genomics and Proteomics, Translational Pharmacology and Translational Onco-Immunology. There is well-established collaboration with the Departments of Urology, Uro-Pathology, Molecular Diagnostic Pathology, Computational Sciences, Radiotherapy and Nuclear Medicine. I have an extensive collaboration with partners from academia and industry, both nationally and internationally.